Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?

5Citations
Citations of this article
111Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Antiretroviral drugs are being tried as candidates for the pre-exposure prophylaxis (PrEP) against HIV for a considerable period, due to their potential for immediate inhibition of viral replication. Discrepancies in the findings called for a critical review of the relevant efforts and their outcomes. A systematic literature search identified 143 eligible articles of which only 5 reported complete findings while another 11 were still ongoing. Observed moderate efficacy and good safety profile seemed to identify PrEP as a promising step for minimizing the spread of HIV to relatively unaffected population and controlling the epidemic among high risk population groups. But the duration of this efficacy was found to depend heavily on the availability, adherence and other related issues like cost, political commitment, ethical consideration etc. To prevent potential cultural and behavioral modifications, proper pre-administration counseling also seemed critical for the success of PrEP as a cost-effective intervention with adequate coverage.

Cite

CITATION STYLE

APA

Yu, W., Wang, L., Han, N., Zhang, X., Mahapatra, T., Mahapatra, S., … Zhao, J. (2016). Pre-exposure prophylaxis of HIV: A right way to go or a long way to go? Artificial Cells, Nanomedicine and Biotechnology, 44(1), 201–208. https://doi.org/10.3109/21691401.2014.934458

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free